PMID- 22153602
OWN - NLM
STAT- MEDLINE
DCOM- 20120906
LR  - 20151119
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 76
IP  - 3
DP  - 2012 Jun
TI  - A cross-market cost comparison of erlotinib versus pemetrexed for first-line 
      maintenance treatment of patients with locally advanced or metastatic 
      non-small-cell lung cancer.
PG  - 465-71
LID - 10.1016/j.lungcan.2011.11.005 [doi]
AB  - Erlotinib and pemetrexed were approved by the European Medicines Agency for 
      first-line maintenance treatment of patients with locally advanced or metastatic 
      non-small-cell lung cancer (NSCLC) to prolong overall survival after first-line 
      therapy. An adjusted, matched, indirect comparison of erlotinib and pemetrexed 
      suggested that survival benefits were not statistically significantly different 
      between treatments. We conducted a cost-comparison analysis of erlotinib versus 
      pemetrexed in first-line maintenance treatment of locally advanced or metastatic, 
      non-squamous NSCLC in France, Germany, Italy and Spain, performed from the 
      perspective of national health-care decision-makers or purchasers. The analysis 
      was limited to direct costs and comprised drug-acquisition costs, administration 
      costs and costs of treating adverse events (AEs). A one-way sensitivity analysis 
      on administration, acquisition and AE costs was also performed. Total monthly 
      per-patient treatment costs for erlotinib in France, Germany, Italy and Spain 
      were euro2140, euro2732, euro1518 and euro2048, respectively, and for pemetrexed euro3453, 
      euro5534, euro2921 and euro3164, respectively. AE cost was greater for pemetrexed in all 
      countries, as was administration cost. As an oral treatment, erlotinib is not 
      associated with any administration costs, except in Germany, where the cost is 
      lower than for pemetrexed. The sensitivity analysis showed acquisition costs to 
      be the main driver of total monthly per-patient costs. Erlotinib appears to be a 
      cost-saving treatment alternative to pemetrexed, producing comparable survival 
      benefits, based on an indirect comparison, at a lower cost.
CI  - Copyright (c) 2011. Published by Elsevier Ireland Ltd.
FAU - Nuijten, Mark J C
AU  - Nuijten MJ
AD  - Ars Accessus Medica, Dorpsstraat 75, NL 1546 LG Jisp, Amsterdam, The Netherlands. 
      marknuijten@planet.nl
FAU - de Castro Carpeno, Javier
AU  - de Castro Carpeno J
FAU - Chouaid, Christos
AU  - Chouaid C
FAU - Vergnenegre, Alain
AU  - Vergnenegre A
FAU - Grossi, Francesco
AU  - Grossi F
FAU - Bischoff, Helge
AU  - Bischoff H
FAU - Heigener, David
AU  - Heigener D
FAU - Walzer, Stefan
AU  - Walzer S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111205
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Glutamates)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 5Z93L87A1R (Guanine)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*economics/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/economics/*pathology
MH  - Drug Costs
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - France
MH  - Germany
MH  - Glutamates/*economics/therapeutic use
MH  - Guanine/*analogs & derivatives/economics/therapeutic use
MH  - Humans
MH  - Italy
MH  - Lung Neoplasms/*drug therapy/economics/*pathology
MH  - Maintenance Chemotherapy/*economics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pemetrexed
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Quinazolines/*economics/therapeutic use
MH  - Spain
EDAT- 2011/12/14 06:00
MHDA- 2012/09/07 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/01/23 00:00 [received]
PHST- 2011/10/31 00:00 [revised]
PHST- 2011/11/05 00:00 [accepted]
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/09/07 06:00 [medline]
AID - S0169-5002(11)00579-4 [pii]
AID - 10.1016/j.lungcan.2011.11.005 [doi]
PST - ppublish
SO  - Lung Cancer. 2012 Jun;76(3):465-71. doi: 10.1016/j.lungcan.2011.11.005. Epub 2011 
      Dec 5.